Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

There are now a growing number of licensed biological therapies for patients with Crohn's
disease. However, there can be significant costs associated with long-term maintenance …

Biologic agents with various mechanisms against Crohn's disease (CD) have been released
and are widely used in clinical practice. However, two anti-tumor necrosis factor (TNF) …

Background: Biologic medications are recommended for treatment of moderately-to-severely
active Crohn disease (CD) or ulcerative colitis (UC) in children. However, many patients …

Background and aims In recent years, biological agents, such as anti-TNF-α blockers, have
been introduced and have shown efficacy in pediatric patients with inflammatory bowel …

METHODS: Among 100 patients, 75 met the inclusion criteria, and 62 were matched by
propensity score. We evaluated time to treatment escalation as the primary outcome and …

Introduction Anti-tumour necrosis factor (TNF) therapy has greatly improved treatment
outcomes in patients with inflammatory bowel disease (IBD), but long-term use is associated …

Background The pharmacokinetics and pharmacodynamics of biosimilar infliximab (IFX-
BioS) in pediatric inflammatory bowel disease (IBD) are poorly investigated. The aim of this …

Background Limited approval of second-line treatments in pediatric inflammatory bowel
disease (pIBD) necessitates optimized use of infliximab (IFX) with proactive therapeutic drug …

Introduction and aims The incidence of paediatric inflammatory bowel disease has
increased in recent decades. The aim of the present study was to evaluate the role of …